Multipartite signaling proteins and uses thereof
The present disclosure relates to compositions and methods for using cells having chemically-induced fusion protein complexes to spatially and temporally control immune cell signal initiation and downstream responses for treating disease. As a preferred example, the present disclosure relates to fusion polypeptides comprising (a) a first polypeptide comprising a first secretion signal, a first multimerization domain, a first transmembrane domain, and an actuator domain, (b) a viral self-cleaving polypeptide, and (c) a second polypeptide comprising a second secretion signal, a binding domain that comprises a single chain antibody, a receptor ectodomain, or a ligand, a second multimerization domain, and a second transmembrane domain.
1. A fusion polypeptide comprising from 5′ to 3′:
(a) a first polypeptide comprising a first secretion signal, a first multimerization domain, a first transmembrane domain, and an actuator domain;
(b) a viral self-cleaving polypeptide; and
(c) a second polypeptide comprising a second secretion signal; a binding domain that comprises a single chain antibody, a receptor ectodomain, or a ligand; a second multimerization domain; and a second transmembrane domain.
2. The fusion polypeptide of claim 1 , wherein the viral self-cleaving polypeptide comprises a viral 2A polypeptide.
3. The fusion polypeptide of claim 2 , wherein the viral 2A polypeptide is selected from the group consisting of: a foot-and-mouth disease virus (FMDV) 2A peptide, an equine rhinitis A virus (ERAV) 2A peptide, a Thosea asigna virus (TaV) 2A peptide, a porcine teschovirus-1 (PTV-1) 2A peptide, a Theilovirus 2A peptide, and an encephalomyocarditis virus 2A peptide.
4. The fusion polypeptide of claim 1 , wherein the first and second secretion signals are the same or different.
5. The fusion polypeptide of claim 1 , wherein the first and second multimerization domains are the same or different.
6. The fusion polypeptide of claim 1 , wherein the multimerization domains of the first and second polypeptides associate with a bridging factor selected from the group consisting of: rapamycin or a rapalog thereof, coumermycin or a derivative thereof, gibberellin or a derivative thereof, abscisic acid (ABA) or a derivative thereof, methotrexate or a derivative thereof, cyclosporin A or a derivative thereof, FK506/cyclosporin A (FKCsA) or a derivative thereof, and trimethoprim (Tmp)-synthetic ligand for FK506 binding protein (FKBP) (SLF) or a derivative thereof.
7. The fusion polypeptide of claim 6 , wherein the first and second multimerization domains are a pair selected from the group consisting of: FKBP and FKBP12-rapamycin binding (FRB), FKBP and calcineurin, FKBP and cyclophilin, FKBP and bacterial dihydrofolate reductase (DHFR), calcineurin and cyclophilin, and PYR1-like 1 (PYL1) and abscisic acid insensitive 1 (ABI1).
8. The fusion polypeptide of claim 7 , wherein the bridging factor is AP21967, sirolimus, everolimus, novolimus, pimecrolimus, ridaforolimus, tacrolimus, temsirolimus, umirolimus, or zotarolimus.
9. The fusion polypeptide of claim 1 , wherein the first multimerization domain comprises a first FKBP polypeptide or variant thereof, and the second multimerization domain comprises a first FRB polypeptide or variant thereof.
10. The fusion polypeptide of claim 1 , wherein the first multimerization domain comprises a first FRB polypeptide or variant thereof, and the second multimerization domain comprises a first FKBP polypeptide or variant thereof.
11. The fusion polypeptide of claim 10 ,
wherein the first polypeptide further comprises a 4-1BB costimulatory domain, and wherein the first FRB polypeptide or variant thereof comprises a FRB T2098L multimerization domain, wherein the first transmembrane domain comprises a CD8α transmembrane domain, wherein the actuator domain comprises a CD3ζ actuator domain;
wherein the viral self-cleaving polypeptide comprises a viral 2A polypeptide; and
wherein the binding domain comprises an anti-CD19 scFv binding domain, wherein the first FKBP polypeptide or variant thereof comprises an FKBP12 multimerization domain, and wherein the second transmembrane domain comprises a CD4 transmembrane domain.
12. The fusion polypeptide of claim 10 ,
wherein the first polypeptide further comprises a 4-1BB costimulatory domain, and wherein the first FRB polypeptide or variant thereof comprises a FRB T2098L multimerization domain, wherein the first transmembrane domain comprises a CD8α transmembrane domain, wherein the actuator domain comprises a CD3ζ actuator domain;
wherein the viral self-cleaving polypeptide comprises a viral 2A polypeptide; and
wherein the binding domain comprises an anti-BCMA scFv binding domain, wherein the first FKBP polypeptide comprises an FKBP12 multimerization domain, and wherein the second transmembrane domain comprises a CD4 transmembrane domain.
13. The fusion polypeptide of claim 1 , wherein the first transmembrane domain is a CD4, CD8 or CD28 transmembrane domain.
14. The fusion polypeptide of claim 1 , wherein the first transmembrane domain is a CD8 transmembrane domain.
15. The fusion polypeptide of claim 1 , wherein the second transmembrane domain is a CD4, CD8 or CD28 transmembrane domain.
16. The fusion polypeptide of claim 1 , wherein the second transmembrane domain is a CD4 transmembrane domain.
17. The fusion polypeptide of claim 1 , wherein the actuator domain comprises a lymphocyte receptor signaling domain.
18. The fusion polypeptide of claim 1 , wherein the actuator domain comprises one or a plurality of immunoreceptor tyrosine-based activation motifs (ITAMs).
19. The fusion polypeptide of claim 1 , wherein the actuator domain comprises a lymphocyte receptor signaling domain of a polypeptide selected from the group consisting of: CD3ε, CD3δ, CD3ζ; pre-T cell receptor α (pTα), T cell receptor α (TCRα), T cell receptor β (TCRβ), Fc receptor α (FcR α), Fc receptor β (FcR β), Fc receptor γ (FcRγ), natural-killer group 2, member D (NKG2D), CD79A, CD79B, and any combination thereof.
20. The fusion polypeptide of claim 1 , wherein the first fusion protein further comprises a different actuator domain, a costimulatory domain, an adhesion factor, or any combination thereof.
21. The fusion polypeptide of claim 20 , wherein the costimulatory domain is from a polypeptide selected from the group consisting of: CD27, CD28, CD30, CD40, linker for activation of T-cells (LAT), zeta-chain-associated protein kinase 70 (Zap70), inducible T-cell costimulator (ICOS), DNAX-activation protein 10 (DAP10), 4-1BB, caspase recruitment domain family member 11 (CARD11), herpesvirus entry mediator (HVEM), lymphocyte activating gene 3 (LAG3), signaling lymphocytic activation molecule family member 1 (SLAMF1), lymphocyte-specific protein tyrosine kinase (Lck), fyn oncogene related to src, fgr, yes (Fyn), SH2 domain-containing leukocyte protein of 76 KDa (Slp76), OX40, and any combination thereof.
22. The fusion polypeptide of claim 1 , wherein the actuator domain comprises a cytoplasmic portion that associates with a cytoplasmic signaling protein that is a lymphocyte receptor or signaling domain thereof, a protein comprising a plurality of immunoreceptor tyrosine-based activation motifs (ITAMs), a costimulatory domain, an adhesion factor, or any combination thereof.
23. The fusion polypeptide of claim 1 , further comprising a third polypeptide comprising a costimulatory factor, an immunomodulatory factor, an agonist for a costimulatory factor, an agonist for an immunomodulatory factor, or any combination thereof.
24. The fusion polypeptide of claim 1 , wherein the binding domain comprises a single chain variable fragment (scFv).
25. The fusion polypeptide of claim 1 , wherein the second polypeptide further comprises a linker disposed between the binding domain and the second multimerization domain.
26. The fusion polypeptide of claim 1 , wherein the binding domain specifically binds to a target selected from the group consisting of: α-folate receptor, α v β 6 integrin, B cell maturation antigen (BCMA), B7 homolog 3 (B7-H3), B7 homolog 6 (B7-H6), Carbonic anhydrase IX (CAIX), CD19, CD20, CD22, CD30, CD33, CD37, CD44, CD44v6, CD44v7/8, CD70, CD123, CD138, CD171, carcinoembryonic antigen (CEA), delta like canonical Notch ligand 4 (DLL4), epithelial glycoprotein 2 (EGP-2), epithelial glycoprotein 40 (EGP-40), chondroitin sulfate proteoglycan 4 (CSPG4), epidermal growth factor receptor (EGFR), EGFR family including ErbB2 (HER2), EGFR variant III (EGFRvIII), epithelial cellular adhesion molecule (EPCAM), ephrin type-A receptor 2 (EphA2), fibroblast activation protein alpha (FAP), fetal acetylcholine receptor, frizzled class receptor 7 (Fzd7), ganglioside GD2 (GD2), ganglioside GD3 (GD3), Glypican-3 (GPC3), human oncofetal antigen 5T4 (h5T4), interleukin 11 receptor alpha (IL-11Rα), interleukin 13 receptor alpha 2 (IL13R-α2), κ light chain, λ light chain, Lewis Y antigen (LeY), L1 cell adhesion molecule (L1CAM), melanoma antigen gene family member A1 (MAGE-A1), mesothelin, major histocompatibility complex (MHC) presented peptides, mucin 1, cell surface associated (MUC1), mucin 16, cell surface associated (MUC16), neural cell adhesion molecule (NCAM), NKG2D ligands, Notch1, Notch2/3, New York esophageal squamous cell carcinoma 1 (NY-ESO-1), preferentially expressed antigen of melanoma (PRAME), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), Survivin, tumor associate glycoprotein 72 (TAG-72), telomerase reverse transcriptase (TERT), vascular endothelial growth factor receptor 2 (VEGFR2), and receptor tyrosine kinase-like orphan receptor 1 (ROR1).